The second, reporting WES data on germline DNA samples from 1162 prevalently adult sarcoma patients (124 HGOS) found that 55% of patients had an excess of pathogenic germline variants in the 72 pan-sarcoma genes, such as TP53, BRCA2, ataxia telangiectasia mutated (ATM), ataxia telangiectasia and Rad3 related (ATR), and ERCC2 [33]. This evidence concerns the gene TP53 and sarcoma.